# Anifrolumab for Hidradenitis Suppurativa

> **NCT06374212** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 15 (estimated)

## Conditions studied

- Hidradenitis Suppurativa
- Acne Inversa
- Hidradenitis

## Interventions

- **DRUG:** Anifrolumab

## Key facts

- **NCT ID:** NCT06374212
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-21
- **Primary completion:** 2026-01-22
- **Final completion:** 2026-04
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06374212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06374212, "Anifrolumab for Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06374212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*